Previous Section
Review Articles
41. Progress in neuroprotection in Parkinson's disease.
- Author
- Schapira AH;
- Institution
- University Department of Clinical Neurosciences, Institute of Neurology, University College London, London, UK. a.schapira@medsch.ucl.ac.uk
- Journal
- Eur J Neurol. 2008 Apr;15 Suppl 1:5-13.
- Abstract URL
- Click here to view abstract
42. Neurotrophic factors as a therapeutic target for Parkinson's disease.
- Author
- Evans JR; Barker RA;
- Institution
- University of Cambridge, Cambridge Centre for Brain Repair, Department of Clinical Neuroscience, UK. jre24@cam.ac.uk
- Journal
- Expert Opin Ther Targets. 2008 Apr;12(4):437-47.
- Abstract URL
- Click here to view abstract
43. Potential therapeutic targets for Parkinson's disease.
- Author
- Stoessl J;
- Institution
- University of British Columbia and Vancouver Coastal Health, Pacific Parkinson's Research Centre & National Parkinson Foundation Centre of Excellence, 2221 Wesbrook Mall, Vancouver, BC, V6T 2B5, Canada. jstoessl@interchange.ubc.ca.
- Journal
- Expert Opin Ther Targets. 2008 Apr;12(4):425-36.
- Abstract URL
- Click here to view abstract
44. The effectiveness of exercise interventions for people with Parkinson's disease: a systematic review and meta-analysis.
- Author
- Goodwin VA; Richards SH; Taylor RS; Taylor AH; Campbell JL;
- Institution
- Primary Care Research Group, Peninsula Medical School, Exeter, United Kingdom. victoria.goodwin@pms.ac.uk
- Journal
- Mov Disord. 2008 Apr 15;23(5):631-40.
- Abstract URL
- Click here to view abstract
45. CBT for the treatment of depression in Parkinson's disease: a promising nonpharmacological approach.
- Author
- Dobkin RD; Menza M; Bienfait KL;
- Institution
- Department of Psychiatry, UMDNJ/Robert Wood Johnson Medical School, 675 Hoes Lane, Room D-317, Piscataway, NJ 08854, USA. dobkinro@umdnj.edu
- Journal
- Expert Rev Neurother. 2008 Jan;8(1):27-35.
- Abstract URL
- Click here to view abstract
46. Role of tolcapone in the treatment of Parkinson's disease.
- Author
- Leegwater-Kim J; Waters C;
- Institution
- Lahey Clinic, Department of Neurology, 41 Mall Road, Burlington, MA 01805, USA. leegwa00@lahey.org
- Journal
- Expert Rev Neurother. 2007 Dec;7(12):1649-57.
- Abstract URL
- Click here to view abstract
47. Drug Insight: impulse control disorders and dopamine therapies in Parkinson's disease.
- Author
- Potenza MN; Voon V; Weintraub D;
- Institution
- Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, New Haven, CT 06519, USA. marc.potenza@yale.edu
- Journal
- Nat Clin Pract Neurol. 2007 Dec;3(12):664-72.
- Abstract URL
- Click here to view abstract
48. Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease.
- Author
- Steiger M;
- Institution
- Walton Centre for Neurology and Neurosurgery, NHS Trust, Liverpool, UK. malcolm.steiger@thewaltoncentre.nhs.uk
- Journal
- Eur J Neurol. 2008 Jan;15(1):6-15. Epub 2007 Nov 27.
- Abstract URL
- Click here to view abstract
49. Parkinson's disease: a genetic perspective.
- Author
- Belin AC; Westerlund M;
- Institution
- Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. andrea.carmine.belin@ki.se
- Journal
- FEBS J. 2008 Apr;275(7):1377-83. Epub 2008 Feb 12.
- Abstract URL
- Click here to view abstract
50. Parkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion.
- Author
- Sydow O;
- Institution
- Department of Neurology, Karolinska University Hospital, Stockholm, Sweden. olof.sydow@karolinska.se
- Journal
- FEBS J. 2008 Apr;275(7):1370-6. Epub 2008 Feb 12.
- Abstract URL
- Click here to view abstract
